Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Argyropoulos, S.V.
and
Nutt, D.J.
1999.
The use of benzodiazepines in anxiety and other disorders.
European Neuropsychopharmacology,
Vol. 9,
Issue. ,
p.
S407.
Pélissolo, Antoine
Notides, Christine
Lépine, Jean-Pierre
and
Bisserbe, Jean-Claude
1999.
Anxiolytic and hypnotic use by general hospital inpatients.
General Hospital Psychiatry,
Vol. 21,
Issue. 2,
p.
79.
Freeman, H. L.
1999.
Unconsciousness and post-traumatic stress disorder.
British Journal of Psychiatry,
Vol. 174,
Issue. 1,
p.
79.
Rischbieth, Sally C
and
Goldney, Robert D
1999.
A Comparison of Private and Public Psychiatry in Three Hospitals.
Australasian Psychiatry,
Vol. 7,
Issue. 1,
p.
20.
Mattila-Evenden, Johan Franck, Ulf, Marja
2001.
A study of benzodiazepine users claiming drug-induced psychiatric morbidity.
Nordic Journal of Psychiatry,
Vol. 55,
Issue. 4,
p.
271.
Nutt, David J.
and
Malizia, Andrea L.
2001.
New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder.
British Journal of Psychiatry,
Vol. 179,
Issue. 5,
p.
390.
Lekka, Nicoletta P.
Paschalis, Christos
and
Beratis, Stavroula
2002.
Suicide attempts in high-dose benzodiazepine users.
Comprehensive Psychiatry,
Vol. 43,
Issue. 6,
p.
438.
Faravelli, C.
Rosi, S.
and
Truglia, E.
2002.
Anxiety Disorders.
p.
313.
Currie, Kevin S.
2003.
Burger's Medicinal Chemistry and Drug Discovery.
p.
525.
Rouleau, Annick
Proulx, Chantal
O’Connor, Kieron
Bélanger, Claude
and
Dupuis, Gilles
2004.
Usage des benzodiazépines chez les personnes âgées : état des connaissances.
Santé mentale au Québec,
Vol. 28,
Issue. 2,
p.
149.
Nash, Jon
and
Nutt, David J
2004.
Psychopharmacology of anxiety.
Psychiatry,
Vol. 3,
Issue. 4,
p.
11.
Raju, Bangaru
and
Meagher, David
2005.
Patient-controlled benzodiazepine dose reduction in a community mental health service.
Irish Journal of Psychological Medicine,
Vol. 22,
Issue. 2,
p.
42.
Nash, J.R.
and
Nutt, D.J.
2005.
Anxiety and Anxiolytic Drugs.
Vol. 169,
Issue. ,
p.
469.
2005.
The Maudsley 2005-2006 Prescribing Guidelines.
p.
135.
Oude Voshaar, Richard C.
Verkes, Robbert-Jan
van Luijtelaar, Gilles L.J.M.
Edelbroek, Peter M.
and
Zitman, Frans G.
2005.
Effects of Additional Oxazepam in Long-Term Users of Oxazepam.
Journal of Clinical Psychopharmacology,
Vol. 25,
Issue. 1,
p.
42.
Nutt, David J.
2005.
Overview of Diagnosis and Drug Treatments of Anxiety Disorders.
CNS Spectrums,
Vol. 10,
Issue. 1,
p.
49.
Haw, Camilla
and
Stubbs, Jean
2007.
Benzodiazepines — a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital.
Journal of Psychopharmacology,
Vol. 21,
Issue. 6,
p.
645.
Nash, Jon R.
and
Nutt, David J.
2007.
Handbook of Contemporary Neuropharmacology.
Meagher, David
Pullela, Ananth
Meisinger, Marek
Geaney, Niamh
and
O'Brien, Sinead
2008.
Five-year follow-up of an evidence-based prescribing intervention.
Psychiatric Bulletin,
Vol. 32,
Issue. 5,
p.
183.
Ator, Nancy A.
Atack, John R.
Hargreaves, Richard J.
Burns, H. Donald
and
Dawson, Gerard R.
2010.
Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at α1 and α2/3 Subtypes.
Journal of Pharmacology and Experimental Therapeutics,
Vol. 332,
Issue. 1,
p.
4.
eLetters
No eLetters have been published for this article.